ASCO 2023 – New Data Highlights Three Studies Showing The Impact Of Vitrakvi On Long-Term Efficacy & Safety In Adult And Pediatric Patients
Dr. Svetlana Babajanyan, MD, Executive Medical Director of Medical Affairs for Oncology at Bayer U.S. Pharmaceuticals discusses new findings from three separate studies analyzing the safety & efficacy of Vitrakvi (larotrectinib) in pediatric and adult patients. These data were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
Svetlana Babajanyan, M.D., is the Executive Medical Director of Medical Affairs for Oncology at Bayer U.S. Pharmaceuticals. Since joining Bayer in 2006, Dr. Babajanyan has reviewed clinical trial protocols and led Bayer sponsored clinical trials in the U.S. She also contributes to the strategic and conceptual aspects of oncology research, participates in the NDA submission and prepares the market for product launch. She also mentors medical directors within U.S. oncology and U.S. medical affairs. She has vast experience in leadership and research in oncology, neurology, diagnostics and hematology, therapeutics for OTC indications, and cosmetics. Dr. Babajanyan has an M.S. in cell molecular biology from the University of New Haven, and an M.D. in internal medicine-pediatrics from the Medical School of Armenia with 12 years of clinical experience in pediatric ICU.
